<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="rcr270102" xml:lang="en" article-type="case-study"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Respirol Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Respirol Case Rep</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2051-3380</journal-id><journal-id journal-id-type="publisher-id">RCR2</journal-id><journal-title-group><journal-title>Respirology Case Reports</journal-title></journal-title-group><issn pub-type="epub">2051-3380</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Ltd</publisher-name><publisher-loc>Chichester, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786966</article-id><article-id pub-id-type="doi">10.1002/rcr2.70102</article-id><article-id pub-id-type="publisher-id">RCR270102</article-id><article-id pub-id-type="other">RCR-24-326.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Unravelling Granulomatous&#x02010;Lymphocytic Interstitial Lung Disease: A Case of Common Variable Immunodeficiency With Unusual Clinical Features and Response to Intravenous Immunoglobulin</article-title></title-group><contrib-group><contrib id="rcr270102-cr-0001" contrib-type="author" corresp="yes"><name><surname>Pragash</surname><given-names>Nirosha</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-0831-8505</contrib-id><xref rid="rcr270102-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>niroshapragash@phcn.vic.gov.au</email></address></contrib><contrib id="rcr270102-cr-0002" contrib-type="author"><name><surname>Mann</surname><given-names>Jennifer</given-names></name><xref rid="rcr270102-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="rcr270102-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="rcr270102-cr-0003" contrib-type="author"><name><surname>Antonov</surname><given-names>Anton</given-names></name><xref rid="rcr270102-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="rcr270102-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="rcr270102-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Thoracic Medicine</named-content>
<institution>Peninsula Health</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="rcr270102-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>The Institute for Breathing and Sleep</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="rcr270102-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Monash Lung Sleep Allergy and Immunology</named-content>
<institution>Monash Health</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Nirosha Pragash (<email>niroshapragash@phcn.vic.gov.au</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue seq="120">2</issue><issue-id pub-id-type="doi">10.1002/rcr2.v13.2</issue-id><elocation-id>e70102</elocation-id><history>
<date date-type="rev-recd"><day>09</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>18</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>10</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 Asian Pacific Society of Respirology--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Respirology Case Reports</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:RCR2-13-e70102.pdf"/><abstract><title>ABSTRACT</title><p>Granulomatous&#x02010;lymphocytic interstitial lung disease (GL&#x02010;ILD) is a rare pulmonary complication associated with common variable immunodeficiency (CVID), complicating diagnosis due to overlapping symptoms with other chronic respiratory conditions. This case involves a 33&#x02010;year&#x02010;old male with a history of sarcoidosis, presenting with recurrent sino&#x02010;pulmonary infections, mediastinal and axillary lymphadenopathy, and significant splenomegaly. Despite initial treatment with prednisolone, his symptoms persisted, and FDG&#x02010;PET imaging showed metabolic activity in the sinuses and lymph nodes. Immunological assessment revealed markedly reduced immunoglobulin levels, leading to intravenous immunoglobulin (IVIG) therapy, which resulted in substantial improvement. A critical learning point is recognising that splenomegaly is commonly associated with CVID, which can aid in distinguishing it from other conditions. This case underscores the importance of considering CVID, with or without GL&#x02010;ILD, as a differential diagnosis in patients with persistent respiratory symptoms and granulomatous lung disease, including sarcoidosis. Further research is needed to optimise treatment strategies for this rare condition.</p></abstract><abstract abstract-type="graphical"><p>Granulomatous&#x02010;lymphocytic interstitial lung disease (GL&#x02010;ILD) is a rare pulmonary complication associated with common variable immunodeficiency (CVID), complicating diagnosis due to overlapping symptoms with other chronic respiratory conditions. This case details the diagnosis and treatment a 33&#x02009;year old male with a history of sarcoidosis, presenting with recurrent sino&#x02010;pulmonary infections, mediastinal and axillary lymphadenopathy, and significant splenomegaly eventually diagnosed with GL&#x02010;ILD with CVID.<boxed-text position="anchor" content-type="graphic" id="rcr270102-blkfxd-0001"><graphic xlink:href="RCR2-13-e70102-g002.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="rcr270102-kwd-0001">granulomatous</kwd><kwd id="rcr270102-kwd-0002">inflammation</kwd><kwd id="rcr270102-kwd-0003">interstitial</kwd><kwd id="rcr270102-kwd-0004">lymphocytic</kwd><kwd id="rcr270102-kwd-0005">sarcoidosis</kwd></kwd-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="4"/><word-count count="2300"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:01.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="rcr270102-ntgp-0001"><fn fn-type="associateEditor" id="rcr270102-note-0001"><p>
<bold>Associate Editor:</bold> Timothy Dempsey</p></fn></fn-group></notes></front><body id="rcr270102-body-0001"><sec id="rcr270102-sec-0001"><label>1</label><title>Introduction</title><p>Granulomatous&#x02010;lymphocytic interstitial lung disease (GL&#x02010;ILD) is a rare and challenging pulmonary manifestation associated with common variable immunodeficiency (CVID) [<xref rid="rcr270102-bib-0001" ref-type="bibr">1</xref>]. GL&#x02010;ILD often presents between the ages of 20 and 50 and shows a higher prevalence in females [<xref rid="rcr270102-bib-0002" ref-type="bibr">2</xref>]. This condition may be incidentally discovered through imaging studies, and around 15% of patients may be asymptomatic [<xref rid="rcr270102-bib-0002" ref-type="bibr">2</xref>]. When symptoms do arise, they typically include exertional dyspnoea and cough, which can be subtle and gradually progressive.</p><p>The condition's diagnostic complexity increases due to its symptom overlap with other chronic respiratory diseases, such as sarcoidosis and chronic obstructive pulmonary disease (COPD). The presence of bronchiectasis is common in GL&#x02010;ILD; however, some patients may not exhibit this feature, complicating the diagnostic process.</p><p>In terms of prognosis, the median survival for patients with GL&#x02010;ILD can range from 5 to 10&#x02009;years post&#x02010;diagnosis, depending on factors such as the underlying cause and treatment response. Lung function tests typically reveal a restrictive pattern, with reductions in forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) [<xref rid="rcr270102-bib-0003" ref-type="bibr">3</xref>]. A decline in DLCO of more than 10% annually has been associated with poorer outcomes [<xref rid="rcr270102-bib-0003" ref-type="bibr">3</xref>].</p></sec><sec id="rcr270102-sec-0002"><label>2</label><title>Case Report</title><p>A 33&#x02010;year&#x02010;old male presented with recurrent sino&#x02010;pulmonary infections against the backdrop of a suspected sarcoidosis diagnosis, which had been established based on a transbronchial lung biopsy. He was diagnosed at the age of 27 when he experienced breathlessness while playing basketball. His lung function tests revealed a preserved FEV1/FVC ratio of 95%, but a moderately impaired diffusing capacity (DLCO) of 59%. Computed tomography (CT) imaging revealed mediastinal and axillary lymphadenopathy, splenomegaly and pulmonary reticulonodular infiltrates as illustrated in Figure&#x000a0;<xref rid="rcr270102-fig-0001" ref-type="fig">1A,B</xref>. Historical bone marrow aspiration and trephine (BMAT) results were unremarkable. A bronchoscopy performed in 2021 showed mild chronic interstitial inflammation and scattered poorly formed granulomas on transbronchial biopsy.</p><fig position="float" fig-type="FIGURE" id="rcr270102-fig-0001"><label>FIGURE 1</label><caption><p>(A) CT chest (November 2017) done at the time of diagnosis demonstrating multiple peribronchovascular, subpleural and perifissural nodular ground&#x02010;glass infiltrates within the mid to lower zones. (B) CT chest (November 2017) demonstrating extensive mediastinal lymphadenopathy. (C) CT chest (September 2023) demonstrating dense consolidation left lower lobe and right upper lobe done. (D) CT chest (May 2024) demonstrating resolution of consolidation following intravenous immunoglobulin (IVIG) treatment.</p></caption><graphic xlink:href="RCR2-13-e70102-g001" position="anchor" id="jats-graphic-3"/></fig><p>He was started on a tapering course of prednisolone in July 2021; however, this treatment provided minimal perceived benefit. The patient also has a history of chronic rhinosinusitis (CRS) and underwent septoplasty, turbinoplasty, and functional endoscopic sinus surgery (FESS) in March 2023. Following these procedures, he was hospitalised in April 2023 with infective sinusitis and multilobar pneumonia. Ear swabs obtained during this admission were positive for Staphylococcus and Haemophilus species. Respiratory fluid cultures, including sputum microscopy, culture, and sensitivity (MCS), were obtained and found to be negative. Despite receiving antibiotics during the admission, there was no meaningful clinical improvement. This lack of response raised suspicion that the observed consolidations on chest CT might be due to inflammatory infiltrates from GL&#x02010;ILD rather than infection. Consequently, multiple courses of prednisolone were administered post&#x02010;admission to target potential inflammation, contributing to the management strategy. FDG&#x02010;PET imaging in September 2023 revealed metabolic activity in the sinuses, mediastinal and hilar lymph nodes and spleen. Azathioprine therapy was commenced as a steroid sparing agent at a low dose of 50&#x02009;mg, but was discontinued after 2&#x02009;weeks due to low globulin levels.</p><p>Due to persistently low total protein and globulin levels, immunoglobulin levels were assessed, revealing significantly reduced levels of immunoglobulins (IgG&#x02009;&#x0003c;&#x02009;1.4&#x02009;g/L, IgM&#x02009;&#x0003c;&#x02009;0.21&#x02009;g/L, and IgA&#x02009;&#x0003c;&#x02009;0.15&#x02009;g/L). The patient was subsequently managed with 40&#x02009;g of intravenous immunoglobulin (IVIG) therapy monthly. Since initiating IVIG, he has not required any further courses of antibiotics. Pre&#x02010;treatment spirometry indicated an FVC of 72.2% and a DLCO of 58.1%. Following 8 months of IVIG therapy, the patient's spirometry showed marked improvement, with an FVC of 88.6% and a DLCO of 71.8%, highlighting the positive response to treatment and improvement in lung function. Additionally, repeat CT chest scan 6&#x02009;months post IVIG initiation demonstrated marked resolution of airspace opacities and consolidation, as illustrated in Figure&#x000a0;<xref rid="rcr270102-fig-0001" ref-type="fig">1C,D</xref>.</p><p>Referral to an immunologist led to the diagnosis of common variable immunodeficiency (CVID) with granulomatous inflammation. The diagnosis of granulomatous&#x02014;lymphocytic interstitial lung disease (GL&#x02010;ILD) was favoured over pulmonary sarcoidosis.</p></sec><sec sec-type="discussion" id="rcr270102-sec-0003"><label>3</label><title>Discussion</title><p>GL&#x02010;ILD is a significant cause of morbidity and mortality in CVID patients, with progressive fibrosis leading to an estimated lung function decline in the DLCO by more than 10% annually and a medical survival range of 5&#x02013;10&#x02009;years if untreated [<xref rid="rcr270102-bib-0003" ref-type="bibr">3</xref>]. CVID is defined by significantly reduced immunoglobulin levels, specifically low IgG and one or both of low IgA or IgM, coupled with impaired vaccine response to Tdap (Tetanus&#x02010;diphtheria&#x02010;acellular pertussis) or pneumococcal vaccination. GL&#x02010;ILD predisposes individuals to immune dysregulation and non&#x02010;infectious pulmonary manifestations [<xref rid="rcr270102-bib-0004" ref-type="bibr">4</xref>]. Patients with CVID and GL&#x02010;ILD have a higher rate of autoimmune complications [<xref rid="rcr270102-bib-0005" ref-type="bibr">5</xref>], which can manifest as follicular bronchiolitis, nodular lymphoid hyperplasia, granulomatous lung disease, lymphocytic interstitial pneumonia, non&#x02010;specific interstitial pneumonia, or organising pneumonia [<xref rid="rcr270102-bib-0006" ref-type="bibr">6</xref>].</p><p>Splenomegaly can be a distinguishing feature when differentiating between sarcoidosis and CVID with GL&#x02010;ILD as summarised in Table&#x000a0;<xref rid="rcr270102-tbl-0001" ref-type="table">1</xref>. In sarcoidosis, splenomegaly is observed in approximately 5%&#x02013;10% of cases, though it is often asymptomatic and may not require specific treatment unless complications such as hypersplenism arise [<xref rid="rcr270102-bib-0007" ref-type="bibr">7</xref>]. In contrast, splenomegaly is much more common in patients with CVID, occurring in around 30%&#x02013;50% of cases, and is frequently associated with autoimmune cytopenias such as autoimmune hemolytic anaemia and idiopathic thrombocytopenic purpura which is uncommon in sarcoidosis [<xref rid="rcr270102-bib-0008" ref-type="bibr">8</xref>, <xref rid="rcr270102-bib-0009" ref-type="bibr">9</xref>]. This higher prevalence of splenomegaly in CVID, particularly in patients with granulomatous inflammation, serves as a useful clinical clue to differentiate it from sarcoidosis, as seen in our patient [<xref rid="rcr270102-bib-0009" ref-type="bibr">9</xref>]. Diagnostic differentiation is essential due to the worse prognosis associated with untreated GL&#x02010;ILD, which can lead to pulmonary fibrosis and severe lung function decline. In addition to splenomegaly, features such as recurrent infections, lymphocytic interstitial pneumonia, and non&#x02010;infectious inflammation are indicative of CVID with GL&#x02010;ILD. Conversely, lupus pernio and certain cutaneous manifestations are exclusive to sarcoidosis [<xref rid="rcr270102-bib-0004" ref-type="bibr">4</xref>].</p><table-wrap position="float" id="rcr270102-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Key differentiating features of GL&#x02010;ILD and sarcoidosis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Feature</th><th align="center" valign="bottom" rowspan="1" colspan="1">GL&#x02010;ILD (CVID&#x02010;associated)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sarcoidosis</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Immunoglobulin levels</td><td align="center" valign="top" rowspan="1" colspan="1">Low IgG, often with low IgA/IgM</td><td align="center" valign="top" rowspan="1" colspan="1">Typically normal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vaccine response</td><td align="center" valign="top" rowspan="1" colspan="1">Poor or absent</td><td align="center" valign="top" rowspan="1" colspan="1">Normal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Splenomegaly</td><td align="center" valign="top" rowspan="1" colspan="1">30%&#x02013;50%</td><td align="center" valign="top" rowspan="1" colspan="1">5%&#x02013;10%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Autoimmune cytopenias</td><td align="center" valign="top" rowspan="1" colspan="1">Common</td><td align="center" valign="top" rowspan="1" colspan="1">Rare</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Specific skin manifestations</td><td align="center" valign="top" rowspan="1" colspan="1">Absent</td><td align="center" valign="top" rowspan="1" colspan="1">Lupus pernio (exclusive)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prognosis without treatment</td><td align="center" valign="top" rowspan="1" colspan="1">High risk of fibrosis and poor outcomes</td><td align="center" valign="top" rowspan="1" colspan="1">Variable and better prognosis</td></tr></tbody></table></table-wrap><p>Granulomatous lymphocytic interstitial lung disease (GL&#x02010;ILD) commonly presents between the ages of 20 and 50, with a higher incidence observed in females [<xref rid="rcr270102-bib-0002" ref-type="bibr">2</xref>]. It is often detected incidentally through imaging studies, with approximately 15% of patients not exhibiting any symptoms [<xref rid="rcr270102-bib-0002" ref-type="bibr">2</xref>]. When symptoms are present, they generally develop gradually, with exertional dyspnoea and cough being the most common [<xref rid="rcr270102-bib-0010" ref-type="bibr">10</xref>]. The severity of dyspnoea typically correlates with the extent of restrictive lung disease [<xref rid="rcr270102-bib-0010" ref-type="bibr">10</xref>]. Additionally, reduced exercise capacity, fatigue, and malaise can arise from expiratory airflow limitations, increased physiological dead space, hypoxemia, hypercapnia, or deconditioning. Persistent non&#x02010;productive cough is common, although up to 80% of patients with GL&#x02010;ILD may also experience sputum production and occasional wheezing, particularly if bronchiectasis is present [<xref rid="rcr270102-bib-0010" ref-type="bibr">10</xref>]. The early respiratory symptoms of GL&#x02010;ILD can be challenging to diagnose due to their overlap with other chronic conditions, such as sarcoidosis and chronic obstructive pulmonary disease (COPD) [<xref rid="rcr270102-bib-0010" ref-type="bibr">10</xref>]. When bronchiectasis is suspected, especially in individuals with primary immunodeficiency disorders, high&#x02010;resolution computed tomography (HRCT) is recommended to confirm the diagnosis.</p><p>Lung function tests usually demonstrate a restrictive pattern, characterised by decreased forced vital capacity (FVC) and reduced DLCO [<xref rid="rcr270102-bib-0003" ref-type="bibr">3</xref>]. The most common CT chest findings in GL&#x02010;ILD include bronchiectasis (observed in over 50% of patients), which was not seen in our patient [<xref rid="rcr270102-bib-0005" ref-type="bibr">5</xref>]. Estimates suggest that among patients with bronchiectasis related to CVID, around 25%&#x02013;40% may have GL&#x02010;ILD as a coexisting condition [<xref rid="rcr270102-bib-0011" ref-type="bibr">11</xref>]. Additional findings include small nodules without a peri&#x02010;lymphatic distribution, consolidation, ground&#x02010;glass changes, and enlarged mediastinal lymph nodes. GL&#x02010;ILD is also more commonly found in the lower lobe distribution [<xref rid="rcr270102-bib-0005" ref-type="bibr">5</xref>].</p><p>Treatment for GL&#x02010;ILD can be challenging. There is little data to guide treatment. A survey carried out by a UK consortium of immunologists, chest physicians, radiologists, and pathologists focused on GL&#x02010;ILD highlighted gaps in treatment understanding [<xref rid="rcr270102-bib-0002" ref-type="bibr">2</xref>]. The study revealed a shared agreement that optimising immunoglobulin therapy should occur before starting additional specific treatments for GL&#x02010;ILD [<xref rid="rcr270102-bib-0002" ref-type="bibr">2</xref>]. Ninety percent of the participants agreed that corticosteroids should be the initial treatment, while at least 80% concurred that the second&#x02010;line options should include azathioprine, rituximab, and mycophenolate [<xref rid="rcr270102-bib-0006" ref-type="bibr">6</xref>].</p><p>This case report details a 33&#x02010;year&#x02010;old male with a history of suspected sarcoidosis who later developed recurrent sino&#x02010;pulmonary infections. Initial diagnosis of sarcoidosis was based on imaging and biopsy findings, with persistent symptoms and radiological change prompting further investigation. Despite a treatment trial with prednisolone, the patient's condition remained problematic, leading to the diagnosis of CVID with granulomatous inflammation. Treatment with intravenous immunoglobulin (IVIG) resulted in significant clinical improvement, and further investigation suggested the possibility of GL&#x02010;ILD. A key educational takeaway from this case is the importance of considering CVID, with or without GL&#x02010;ILD, as a differential diagnosis for patients diagnosed with sarcoidosis or other granulomatous lung diseases. The presence of splenomegaly and autoimmune cytopenias, along with recurrent sino&#x02010;pulmonary infections, served as important clues in this diagnostic process. The overall clinical presentation and response to IVIG support the diagnosis of GL&#x02010;ILD.</p></sec><sec id="rcr270102-sec-0004"><title>Author Contributions</title><p>
<bold>Nirosha Pragash:</bold> lead in manuscript preparation and development of subsequent drafts. <bold>Jennifer Mann:</bold> contributed to manuscript revisions and provided critical review. <bold>Anton Antonov:</bold> supervised the case report and provided overall guidance.</p></sec><sec id="rcr270102-sec-0005"><title>Ethics Statement</title><p>The authors declare that appropriate written informed consent was obtained for the publication of this manuscript and accompanying images.</p></sec><sec sec-type="COI-statement" id="rcr270102-sec-0006"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><sec sec-type="data-availability" id="rcr270102-sec-0008"><title>Data Availability Statement</title><p>Data sharing not applicable to this article as no datasets were generated or analysed during the current study.</p></sec><ref-list content-type="cited-references" id="rcr270102-bibl-0001"><title>References</title><ref id="rcr270102-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="rcr270102-cit-0001">
<string-name>
<given-names>A.</given-names>
<surname>Khreisat</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Xin</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Dado</surname>
</string-name>, &#x0201c;<article-title>Granulomatous Lymphocyte Interstitial Lung Disease: A Rare Complication of Common Variable Immunodeficiency Managed With Azathioprine and Rituximab</article-title>,&#x0201d; <source>Cureus</source>
<volume>16</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>1</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="rcr270102-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="rcr270102-cit-0002">
<string-name>
<given-names>J. R.</given-names>
<surname>Hurst</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Verma</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Lowe</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous&#x02010;Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders</article-title>,&#x0201d; <source>Journal of Allergy and Clinical Immunology</source>
<volume>5</volume>, no. <issue>4</issue> (<year>2017</year>): <fpage>938</fpage>&#x02013;<lpage>945</lpage>.</mixed-citation></ref><ref id="rcr270102-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="rcr270102-cit-0003">
<string-name>
<given-names>V.</given-names>
<surname>Cottin</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Crestani</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Valeyre</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Wallaert</surname>
</string-name>, and <string-name>
<given-names>J. F.</given-names>
<surname>Cordier</surname>
</string-name>, &#x0201c;<article-title>Diagnosis of Severe Chronic Restrictive Respiratory Disorders</article-title>,&#x0201d; <source>Revista de la Sociedad Espa&#x000f1;ola de Neumolog&#x000ed;a y Cirug&#x000ed;a Tor&#x000e1;cica</source>
<volume>23</volume>, no. <issue>5 Pt 2</issue> (<year>2006</year>): <fpage>12S109</fpage>&#x02013;<lpage>12S124</lpage>.</mixed-citation></ref><ref id="rcr270102-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="rcr270102-cit-0004">
<string-name>
<given-names>C.</given-names>
<surname>Cunningham&#x02010;Rundles</surname>
</string-name>, &#x0201c;<article-title>Common Variable Immune Deficiency: Dissection of the Variable</article-title>,&#x0201d; <source>Immunological Reviews</source>
<volume>287</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>145</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">30565247</pub-id>
</mixed-citation></ref><ref id="rcr270102-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="rcr270102-cit-0005">
<string-name>
<given-names>L. J.</given-names>
<surname>Mechanic</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Dikman</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Cunningham&#x02010;Rundles</surname>
</string-name>, &#x0201c;<article-title>Granulomatous Disease in Common Variable Immunodeficiency</article-title>,&#x0201d; <source>Annals of Internal Medicine</source>
<volume>127</volume>, no. <issue>8</issue> (<year>1997</year>): <fpage>613</fpage>&#x02013;<lpage>617</lpage>.<pub-id pub-id-type="pmid">9341059</pub-id>
</mixed-citation></ref><ref id="rcr270102-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="rcr270102-cit-0006">
<string-name>
<given-names>D.</given-names>
<surname>Bouvry</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Mouthon</surname>
</string-name>, <string-name>
<given-names>P. Y.</given-names>
<surname>Brillet</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Granulomatous&#x02013;Lymphocytic Interstitial Lung Disease: A New Subgroup of Interstitial Lung Disease Associated With Common Variable Immunodeficiency</article-title>,&#x0201d; <source>Medicine (Baltimore)</source>
<volume>91</volume>, no. <issue>2</issue> (<year>2012</year>): <fpage>103</fpage>&#x02013;<lpage>115</lpage>.<pub-id pub-id-type="pmid">22391472</pub-id>
</mixed-citation></ref><ref id="rcr270102-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="rcr270102-cit-0007">
<string-name>
<given-names>D. G.</given-names>
<surname>James</surname>
</string-name> and <string-name>
<given-names>O. P.</given-names>
<surname>Sharma</surname>
</string-name>, &#x0201c;<article-title>Splenomegaly in Sarcoidosis: A Report of 39 Cases</article-title>,&#x0201d; <source>Acta Medica Scandinavica</source>
<volume>207</volume>, no. <issue>1&#x02013;2</issue> (<year>1980</year>): <fpage>83</fpage>&#x02013;<lpage>88</lpage>.</mixed-citation></ref><ref id="rcr270102-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="rcr270102-cit-0008">
<string-name>
<given-names>L.</given-names>
<surname>Mellemkjaer</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Hammarstr&#x000f6;m</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Andersen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cancer Risk Among Patients With IgA Deficiency or Common Variable Immunodeficiency and Their Relatives: A Combined Danish and Swedish Study</article-title>,&#x0201d; <source>Clinical and Experimental Immunology</source>
<volume>130</volume>, no. <issue>3</issue> (<year>2002</year>): <fpage>495</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">12452841</pub-id>
</mixed-citation></ref><ref id="rcr270102-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="rcr270102-cit-0009">
<string-name>
<given-names>I.</given-names>
<surname>Quinti</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Soresina</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Spadaro</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long&#x02010;Term Follow&#x02010;Up and Outcome of a Large Cohort of Patients With Common Variable Immunodeficiency</article-title>,&#x0201d; <source>Journal of Clinical Immunology</source>
<volume>27</volume>, no. <issue>3</issue> (<year>2007</year>): <fpage>308</fpage>&#x02013;<lpage>316</lpage>.<pub-id pub-id-type="pmid">17510807</pub-id>
</mixed-citation></ref><ref id="rcr270102-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="rcr270102-cit-0010">
<string-name>
<given-names>C. A.</given-names>
<surname>Bates</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Ellison</surname>
</string-name>, <string-name>
<given-names>D. A.</given-names>
<surname>Lynch</surname>
</string-name>, <string-name>
<given-names>C. D.</given-names>
<surname>Cool</surname>
</string-name>, <string-name>
<given-names>K. K.</given-names>
<surname>Brown</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Routes</surname>
</string-name>, &#x0201c;<article-title>Granulomatous&#x02010;Lymphocytic Lung Disease Shortens Survival in Common Variable Immunodeficiency</article-title>,&#x0201d; <source>Journal of Allergy and Clinical Immunology</source>
<volume>114</volume>, no. <issue>2</issue> (<year>2004</year>): <fpage>415</fpage>&#x02013;<lpage>421</lpage>.<pub-id pub-id-type="pmid">15316526</pub-id>
</mixed-citation></ref><ref id="rcr270102-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="rcr270102-cit-0011">
<string-name>
<given-names>M. A.</given-names>
<surname>Cunningham</surname>
</string-name> and <string-name>
<given-names>S. P.</given-names>
<surname>Linton</surname>
</string-name>, &#x0201c;<article-title>Bronchiectasis and Granulomatous&#x02010;Lymphocytic Interstitial Lung Disease (GL&#x02010;ILD) in Common Variable Immunodeficiency: Diagnostic Challenges and Co&#x02010;Occurrence</article-title>,&#x0201d; <source>Journal of Clinical Immunology</source>
<volume>40</volume>, no. <issue>5</issue> (<year>2020</year>): <fpage>510</fpage>&#x02013;<lpage>517</lpage>.</mixed-citation></ref></ref-list></back></article>